利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

54 条记录 (耗时 0.031 秒)

    Self-emulsifying pharmaceutical compositions of rhein or diacerein
    1.
    发明授权
    Self-emulsifying pharmaceutical compositions of rhein or diacerein 有权
    大黄酸或双醋瑞因的自乳化药物组合物

    公开(公告)号：US09192596B2

    公开(公告)日：2015-11-24

    申请号：US14636499

    申请日：2015-03-03

    申请人： WOCKHARDT RESEARCH CENTRE

    发明人： Premchand Nakhat ,  Prashant Mandaogade ,  Girish Kumar Jain ,  Munish Talwar

    IPC分类号： A61K9/48 ,  A61K9/64 ,  A61K31/235 ,  A61K9/107 ,  A61K31/222 ,  A61K47/44

    CPC分类号： A61K31/235 ,  A61K9/1075 ,  A61K9/4825 ,  A61K9/4858 ,  A61K31/222 ,  A61K47/44

    摘要： The invention relates to self emulsifying drug delivery system based compositions of rhein or diacerein, or salts or esters or prodrugs thereof which are bioequivalent to a 50 mg diacerein formulation marketed under the trade name Art 50®. The compositions exhibit no variability in fed and fasted state conditions. The compositions also result in significant reduction in side effects such as, soft stools effects as compared to Art 50®. The invention also relates to methods for preparing such compositions.

    摘要翻译： 本发明涉及基于大黄酸或双醋瑞因或其盐或酯或前药的基于自乳化药物递送系统的组合物，其与以商品名Art 50销售的50mg双醋瑞因制剂是生物等效的。 组合物在进食和禁食状态下表现出不变性。 与Art 50相比，组合物还导致副作用显着降低，例如软粪便效应。 本发明还涉及制备这种组合物的方法。

    Antidepressant Oral Liquid Compositions
    6.
    发明申请
    Antidepressant Oral Liquid Compositions 失效
    抗抑郁口服液体组合物

    公开(公告)号：US20120196917A1

    公开(公告)日：2012-08-02

    申请号：US13443698

    申请日：2012-04-10

    申请人： Ramesh Sesha

    发明人： Ramesh Sesha

    IPC分类号： A61K31/381 ,  A61P25/24 ,  A61P3/10 ,  C07D333/20

    CPC分类号： A61K31/381

    摘要： The invention provides for the first time an oral liquid composition of duloxetine or its pharmaceutically equivalent derivatives like salts, isomers, complexes, polymorphs, hydrates or esters thereof. The duloxetine or its pharmaceutically equivalent derivative is present from about 2 mg to approximately 200 mg; and a buffering agent was used to stabilize the acid sensitive duloxetine. The composition has duloxetine from about 0.1 mEq to about 2.5 mEq per mg of duloxetine. The invention further discloses an oral liquid composition of duloxetine or its pharmaceutically equivalent derivative wherein the degradation product 1-Naphthol is less than 0.01%. Also provided is a method for treating of major depressive disorder and or diabetic peripheral neuropathic pain comprising administering to a mammal in need of such treatment a therapeutically effective amount of a composition.

    摘要翻译： 本发明首次提供度洛西汀或其药学上相当的衍生物如盐，异构体，复合物，多晶型物，水合物或酯的口服液体组合物。 度洛西汀或其药学上相当的衍生物存在约2mg至约200mg; 并使用缓冲剂来稳定酸敏感的度洛西汀。 该组合物具有约0.1mEq至约2.5mEq / mg度洛西汀的度洛西汀。 本发明还公开了度洛西汀或其药学上等同的衍生物的口服液体组合物，其中降解产物1-萘酚小于0.01％。 还提供了治疗重度抑郁障碍和/或糖尿病性周围神经性疼痛的方法，包括向需要这种治疗的哺乳动物施用治疗有效量的组合物。